
Benzinga Pro data, Novavax (NASDAQ:NVAX) reported Q4 sales of $222.20 million. Earnings fell to a loss of $846.28 million, resulting in a 162.47% decrease from last quarter. In Q3, Novavax brought in $178.84 million in sales but lost $322.43 million in earnings.